Drug
Apl 3007
Apl 3007: highest development phase Phase 2, developed by Apellis Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Apellis Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| APL-3007, pegcetacoplan (APL-2) NCT07215390 | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration |
Latest
No recent events.
Follow Apl 3007 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.